Temsirolimus (Torisel)

Number: 0873


Aetna considers temsirolimus (Torisel) medically necessary for the following indications:

  • Endometrial carcinoma - single agent treatment of endometrial carcinoma 
  • Renal cell carcinoma (RCC) - relapsed, metastatic or unresectable RCC 
  • Soft tissue sarcoma - perivascular epithelioid cell tumor (PEComa), angiomyolipoma, or lymphangioleiomyomatosis subtypes.

Continuation of temsirolimus is considered medically necessary for members who meet medical necessity criteria above when there is no evidence of unacceptable toxicity or disease progression on the current regimen.

Aetna considers temsirolimus experimental and investigational for all other indications including the following (not an all-inclusive list):

  • Acute lymphoblastic leukemia
  • Adenoid cystic carcinoma
  • Alzheimer's disease
  • B-cell non-Hodgkin lymphoma (e.g., diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma)
  • Bladder cancer
  • Breast cancer
  • Central nervous system tumors (e.g., ependymoma, gliomas/glioblastoma multiforme, lymphoma, medulloblastoma, and pontine glioma)
  • Cervical cancer
  • Cholangiocarcinoma
  • Colorectal cancer
  • Desmoplastic small round cell tumor
  • Ewing sarcoma
  • Head and neck squamous cell carcinoma
  • Hepatocellular carcinoma
  • Leiomyosarcoma
  • Lung cancer (e.g., lung adenocarcinoma, and non-small cell lung cancer)
  • Melanoma
  • Myelodysplastic syndromes
  • Neuroblastoma
  • Neuroendocrine tumors (e.g., neuroendocrine of pancreas)
  • Osteosarcoma
  • Ovarian cancer
  • Pancreatic cancer
  • Parkinson's disease
  • Prostate cancer
  • Retinoblastoma
  • Rhabdomyosarcoma
  • Thyroid cancer
  • Vaginal cancer.

Dosing Recommendations

Temsirolimus is available as Torisel injection, 25 mg/mL. The recommended dose of temsirolimus for advanced renal cell carcinoma is 25 mg infused over a 30‐60 minute period once a week.

Continued use beyond 3 months (12 weeks) is considered medically necessary for persons with stable disease (tumor size within 25 % of baseline).  Continued use is considered not medically necessary when there is evidence of disease progression or unacceptable toxicity occurs.


Temsirolimus (Torisel ) is an inhibitor of mammalian target of rapamycin (mTOR ). Temsirolimus binds to an intracellular protein (FKBP‐12), and the protein‐drug complex inhibits the activity of mTOR that controls cell division.  Inhibition of mTOR activity resulted in a G1 growth arrest in treated tumor cells.  When mTOR was inhibited, its ability to phosphorylate p70S6k and S6 ribosomal protein, which are downstream of mTOR in the PI3 kinase/AKT pathway was blocked.

Temsirolimus is an intravenous chemotherapeutic agent in the class mTOR inhibitor, and was approved by the U.S. Food and Drug Administration (FDA) in May 2007 for the treatment of advanced renal cell carcinoma in adults.

As a first line treatment for renal cell carcinoma, temsirolimus is generally reserved for member with poor prognosis. Poor‐prognosis is defined as possessing 3 or more predictors of short survival:

  • Lactate dehydrogenase level > 1.5 times upper limit of normal
  • Hemoglobin level < lower limit of normal
  • Corrected serum calcium level > 10 mg/dl (2.5 mmol/liter)
  • Karnofsky performance score 70
  • Two sites of organ metastasis
  • Interval of less than year from original diagnosis to the development of metastatic disease.
The National Comprehensive Cancer Network Drugs & Biologics Compendium (NCCN, 2018) recommends use of temsirolimus in kidney cancer as single-agent therapy for relapse or stage IV disease:
  1. as first-line therapy for clear cell histology and poor or intermediate risk (useful under certain circumstances)
  2. as subsequent therapy for predominant clear cell histology (useful under certain circumstances) 
  3.  as systemic therapy for non-clear cell histology (useful under certain circumstances).

The NCCN Drugs & Biologics Compendium (NCCN, 2018) recommends temsirolimus for endometrioid adenocarcinoma:

  • Primary treatment as a single agent 
    • may be considered for select patients with disease limited to the uterus that is not suitable for primary surgery
    • with or without sequential external beam radiation therapy (EBRT) and brachytherapy for disease not suitable for primary surgery in patients with suspected or gross cervical involvement
    • may be considered preoperatively for patients presenting with ascites and/or disease in the omentum, lymph nodes (including inguinal nodes), ovaries, or peritoneum
    • with or without sequential EBRT and/or brachytherapy for extrauterine pelvic disease
    • with or without EBRT and/or hormonal therapy for distant visceral metastases.
  • Adjuvant treatment for surgically staged patients as a single agent
    • with vaginal brachytherapy and/or sequential external beam radiation therapy (EBRT) in patients with stage IA disease and histologic grade 3 tumors with adverse risk factors present
    • with vaginal brachytherapy and/or sequential EBRT in patients with stage IB disease and histologic grade 3 tumors with no adverse risk factors present
    • with sequential EBRT and/or vaginal brachytherapy in patients with stage IB disease and histologic grade 3 tumors with adverse risk factors present
    • with sequential EBRT with or without vaginal brachytherapy in patients with stage II disease and histologic grade 3 tumors
    • with sequential EBRT with or without vaginal brachytherapy for stage III disease
    • with or without sequential EBRT and vaginal brachytherapy for stage IV disease.
  • Single agent
    • may be considered for isolated metastases
    • for disseminated metastases that have progressed on hormonal therapy
    • with or without sequential palliative external beam radiation therapy (EBRT) for symptomatic, grade 2, 3, or large-volume disseminated metastases or for local/regional recurrence in patients with gross upper abdominal residual disease
    • with sequential EBRT with or without brachytherapy for local/regional recurrence in patients with disease confined to the vagina or in pelvic lymph nodes
    • with sequential EBRT for local/regional recurrence in patients with disease in para-aortic or common iliac lymph nodes
    • with or without sequential tumor-directed EBRT for local/regional recurrence in patients with microscopic residual upper abdominal or peritoneal disease
    • with or without sequential palliative EBRT for local/regional recurrence in patients who have received prior EBRT to site of recurrence.
The NCCN Drugs & Biologics Compendium (NCCN, 2018) recommends temsirloimus for endometrial carcinosarcoma, undifferentiated/dedifferentiated carcinoma; or serous or clear cell endometrial carcinoma as adjuvant therapy as a single agent with or without:
  1. vaginal brachytherapy for stage IA disease (preferred); or
  2. sequential external beam radiation therapy (EBRT) with or without vaginal brachytherapy for stage IB-IV disease.

The NCCN Drugs & Biologics Compendium (2018) on soft tissue sarcoma recommends temsirolimus as single-agent therapy for the treatment of PEComa, recurrent angiomyolipoma, and lymphangioleiomyomatosis.

Torisel (temsirolimus) should not be utilized in the following:

  • Members less than 18 years of age
  • Known hypersensitivity to Torisel (temsirolimus) or any of its excipients
  • Women who are pregnant or lactating
  • Members on concomitant strong CYP3A4 inhibitors or inducers.

Sarcomas / Soft-Tissue Sarcomas

Wagner et al (2015) stated that the combined inhibition of insulin-growth factor type 1 receptor (IGF-1R) and the mTOR has shown activity in pre-clinical models of pediatric sarcoma and in adult sarcoma patients. These researchers evaluated the activity of the anti-IGF-1R antibody cixutumumab with the mTOR inhibitor temsirolimus in patients with relapsed or refractory Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, and other soft tissue sarcoma, using the recommended dosages from a pediatric phase I trial. Cixutumumab 6 mg/kg and temsirolimus 8 mg/m(2) were administered intravenously once-weekly in 4-week cycles to patients less than 30 years. Temsirolimus was escalated to 10 mg/m(2) for subsequent cycles in patients who did not experience unacceptable first-cycle toxicity. A 2-stage design was used to identify a response rate less than 10 or greater than 35 % for each tumor-specific cohort. Tumor tissue was analyzed by immunohistochemistry for potential biomarkers of response. A total of 43 evaluable patients received a median of 2 cycles (range of 1 to 7). No objective responses were observed, and 16 % of patients were progression-free at 12 weeks. Dose-limiting toxicity was observed in 15 (16 %) of 92 cycles. The most common toxicities were mucositis, electrolyte disturbances, and myelosuppression. The majority of patients receiving a second cycle were not eligible for temsirolimus escalation due to first-cycle toxicity. The lack of objective responses precluded correlation with tissue biomarkers. The authors concluded that despite encouraging pre-clinical data, the combination of cixutumumab and temsirolimus did not result in objective responses in this phase II trial of pediatric and young adults with recurrent or refractory sarcoma.

Eroglu et al (2015) stated that the MEK inhibitor, selumetinib, suppresses soft-tissue sarcoma (STS) cell proliferation in-vitro. Mammalian target of rapamycin inhibitors possess modest activity against STS; however, resistance develops via MAPK pathway feedback activation. The combination of selumetinib and temsirolimus synergistically inhibits STS cell line growth. Therefore, a randomized phase II trial of selumetinib versus selumetinib plus temsirolimus was conducted. A total of 71 adults with advanced STS who received less than or equal to 2 prior chemotherapeutics were randomized to selumetinib 75 mg p.o. bid (by mouth, twice-daily) and allowed to cross-over upon progression, or to selumetinib 50 mg p.o. bid plus temsirolimus 20 mg I.V. weekly, with primary end-point of progression-free survival (PFS). There was no difference in PFS between the 2 arms for the overall cohort (median of 1.9 versus 2.1 months); an improved median PFS was observed in the combination arm (n = 11) over single agent (n = 10) in the pre-specified leiomyosarcoma stratum (median of 3.7 versus 1.8 months; p = 0.01). Four-month PFS rate was 50 % (95 % confidence interval [CI]: 0.19 to 0.81) with the combination versus 0 % with selumetinib alone in the leiomyosarcoma cohort. Most common grade 3/4 adverse events with the combination were mucositis (29 %), lymphopenia (26 %), neutropenia and anemia (20 % each). The authors concluded that while single-agent selumetinib has no significant activity in STS, the combination may be active for leiomyosarcomas.

Adenoid Cystic Carcinoma

Liu et al (2014) stated that temsirolimus acts as an mTOR-dependent autophagic inhibitor. In order to clarify its effects and mechanisms on human salivary adenoid cystic carcinoma (ACC), these researchers examined whether temsirolimus induced autophagy as the mTOR inhibitor in ACC, both in-vitro and in-vivo. In this study, MTT assay showed that the inhibition effect of temsirolimus assumed an obvious dose-response relationship on ACC-M cells, and the 50 % inhibitory concentration (IC(50)) approached 20 μmol/L; numerous autophagosomes were observed by the transmission electron microscopy in temsirolimus treatment groups; notably, expression of LC3 and Beclin1 was significantly up-regulated by temsirolimus. More importantly, the xenograft model provided further evidence of temsirolimus-induced autophagy in-vivo by inhibiting mTOR activation as well as up-regulation the expression of Beclin1. The authors concluded that these results suggested that temsirolimus could act as an mTOR inhibitor to induce autophagy in ACC both in-vitro and in-vivo.

Alzheimer's Disease

Jiang et al (2014) stated that accumulation of amyloid-β peptides (Aβ) within brain is a major pathogenic hallmark of Alzheimer's disease (AD). Emerging evidence suggested that autophagy, an important intra-cellular catabolic process, is involved in Aβ clearance. These researchers examined if temsirolimus would promote autophagic clearance of Aβ and thus provide protective effects in cellular and animal models of AD. HEK293 cells expressing the Swedish mutant of APP695 (HEK293-APP695) were treated with vehicle or 100 nM temsirolimus for 24 hours in the presence or absence of 3-methyladenine (5 mM) or Atg5-siRNA, and intra-cellular Aβ levels as well as autophagy biomarkers were measured. Meanwhile, APP/PS1 mice received intra-peritoneal injection of temsirolimus (20 mg/kg) every 2 days for 60 days, and brain Aβ burden, autophagy biomarkers, cellular apoptosis in hippocampus, and spatial cognitive functions were assessed. The results showed that temsirolimus enhanced Aβ clearance in HEK293-APP695 cells and in brain of APP/PS1 mice in an autophagy-dependent manner. Meanwhile, temsirolimus attenuated cellular apoptosis in hippocampus of APP/PS1 mice, which was accompanied by an improvement in spatial learning and memory abilities. The authors concluded that the findings of this study provided the first evidence that temsirolimus promotes autophagic Aβ clearance and exerts protective effects in cellular and animal models of AD, suggesting that temsirolimus administration may represent a new therapeutic strategy for AD treatment.

B-Cell Non-Hodgkin Lymphoma

Fenske et al (2015) conducted a single-arm, phase II clinical trial of combined temsirolimus and bortezomib in patients with relapsed and refractory B-cell non-Hodgkin lymphoma (NHL) using a dosing scheme that was previously tested in multiple myeloma. The patients received bortezomib and temsirolimus weekly on days 1, 8, 15, and 22 of a 35-day cycle. Of 39 patients who received treatment, 3 achieved a complete response (CR) (7.7 %; 95 % CI: 1.6 % to 21 %), and 9 had a partial response (PR) (23 %; 95 % CI: 11 % to 39 %). Thus, the overall response rate (ORR; 12 of 39 patients) was 31 % (95 % CI: 17 % to 48 %), and the median PFS was 4.7 months (95 % CI: 2.1 to 7.8 months; 2 months for patients with diffuse large B-cell lymphoma [n = 18], 7.5 months for those with mantle cell lymphoma [n = 7], and 16.5 months for those with follicular lymphoma [n = 9]). Two extensively treated patients with diffuse large B-cell lymphoma achieved a CR. There were no unexpected toxicities from the combination. The authors concluded that the current results demonstrated that the combination of an mTOR inhibitor and a proteasome inhibitor is safe and has activity in patients with heavily pretreated B-cell NHL. They stated that further studies with this combination are needed in specific subtypes of NHL.

Breast Cancer

Qiao and colleagues (2014) performed a meta-analysis of randomized controlled trials (RCT) in breast cancer patients undergoing chemotherapy using steroid (exemestane) or non-steroid (letrozole) aromatase inhibitors with or without mTOR inhibitors (everolimus). The ORR, PFS, clinical benefit rate (CBR) with 95 % CI, and the major toxicities/adverse effects were analyzed. Data were extracted from 12 studies that meet the selection criteria. Among these, 6 studies that enrolled 3,693 women received treatment of everolimus plus exemestane, or placebo with exemestane. The results showed that everolimus plus exemestane significantly increased the ORR relative risk (relative risk [RR] = 9.18, 95 % CI: 5.21 to 16.15), PFS hazard ratio (HR = 0.44, 95 % CI: 0.41 to 0.48), and clinical benefit rate (RR = 1.92, 95 % CI: 1.69 to 2.17) compared to placebo control, while the risks of stomatitis, rash, hyperglycemia, diarrhea, fatigue, anorexia and pneumonitis also increased. Three studies that enrolled 715 women who received everolimus as neoadjuvant therapy were analyzed. Compared to chemotherapy with placebo, chemotherapy plus everolimus did not increase the ORR (RR = 0.90, 95 % CI: 0.77 to 1.05). Meanwhile, 2 other studies that enrolled 2,104 women examined the effectiveness of temsirolimus (or placebo control) plus letrozole. The results indicated that emsirolimus plus letrozole did not increase the ORR and CBR (p > 0.05). The authors concluded that these data suggested that the combined mTOR inhibitor (everolimus) plus endocrine therapy (exemestane) is superior to endocrine therapy alone. As a neoadjuvant, everolimus did not increase the ORR, while temsirolimus plus letrozole treatment has limited effect on the ORR and the CBR of breast cancer patients.

Central Nervous System Tumors

Piha-Paul et al (2014) noted that pre-clinical findings suggested that combination treatment with bevacizumab and temsirolimus could be effective against malignant pediatric central nervous system (CNS) tumors. A total of 6 pediatric patients were treated as part of a phase I trial with intravenous temsirolimus 25 mg on days 1, 8, 15, and bevacizumab at 5, 10, or 15 mg/kg on day 1 of each 21-day cycle until disease progression or patient withdrawal. The median patient age was 6 years (range of 3 to 14 years). The primary diagnoses were glioblastoma multiforme (n = 2), medulloblastoma (n = 2), pontine glioma (n = 1) and ependymoma (n = 1). All patients had disease refractory to standard-of-care (2 to 3 prior systemic therapies). Grade 3 toxicities possibly related to drugs used occurred in 2 patients: anorexia, nausea, and weight loss in 1, and thrombocytopenia and alanine aminotransferase elevation in another. One patient with glioblastoma multiforme achieved a PR (51 % regression) and 2 patients (with medulloblastoma and pontine glioma) had stable disease (SD) for 4 months or more (20 and 47 weeks, respectively). One other patient (with glioblastoma multiforme) showed 18 % tumor regression (duration of 12 weeks). The authors concluded that the combination of bevacizumab with temsirolimus was well-tolerated and resulted in SD of at least 4 months/PR in 3 out of 6 pediatric patients with chemo-refractory CNS tumors.

Wen et al (2014) stated that inhibition of epidermal growth factor receptor (EGFR) and the mTOR may have synergistic anti-tumor effects in high-grade glioma patients. These investigators conducted a phase I/II study of the EGFR inhibitor erlotinib (150 mg/day) and the mTOR inhibitor temsirolimus. Patients initially received temsirolimus 50 mg weekly, and the dose adjusted based on toxicities. In the phase II component, the primary end-point was 6-month PFS (PFS6) among glioblastoma patients. A total of 22 patients enrolled in phase I, 47 in phase II; 12 phase I patients treated at the maximum tolerated dose (MTD) were included in the phase II cohort for analysis. The MTD was 15 mg temsirolimus weekly with erlotinib 150 mg daily. Dose-limiting toxicities were rash and mucositis. Among 42 evaluable glioblastoma patients, 12 (29 %) achieved SD, but there were no responses, and PFS6 was 13 %. Among 16 anaplastic glioma patients, 1 (6 %) achieved CR, 1 (6 %) PR, and 2 (12.5 %) SD, with PFS6 of 8 %. Tumor levels of both drugs were low, and post-treatment tissue in 3 patients showed no reduction in the mTOR target phosphorylated (phospho-)S6(S235/236) but possible compensatory increase in phospho-Akt(S473). Presence of EGFR variant III, phospho-EGFR, and EGFR amplification did not correlate with survival, but patients with elevated phospho-extracellular signal-regulated kinase or reduced phosphatase and tensin homolog protein expression had decreased PFS at 4 months. The authors concluded that because of increased toxicity, the MTD of temsirolimus in combination with erlotinib proved lower than expected. Insufficient tumor drug levels and redundant signaling pathways may partly explain the minimal anti-tumor activity noted.

NCCN’s Drugs & Biologics Compendium (2015) does not list central nervous system tumors as recommended indications of temsirolimus.

Schiff and associates (2018) conducted a phase 1/2 study of sorafenib and temsirolimus in patients with recurrent glioblastoma.  Patients with recurrent glioblastoma who developed disease progression after surgery or radiotherapy plus temozolomide and with less than or equal to 2 prior chemotherapy regimens were eligible.  The end-point of the phase 1 study was the MTD, using a cohorts-of-3 design.  The 2-stage phase 2 study included separate arms for VEGF inhibitor (VEGFi)-naive patients and patients who progressed after prior VEGFi.  The MTD was sorafenib at a dose of 200 mg twice-daily and temsirolimus at a dose of 20 mg weekly.  In the first 41 evaluable patients who were treated at the phase 2 dose, there were 7 who were free of disease progression at 6 months (PFS at 6 months [PFS6]) in the VEGFi-naive group (17.1 %); this finding met the pre-study threshold of success.  In the prior VEGFi group, only 4 of the first 41 evaluable patients treated at the phase 2 dose achieved PFS6 (9.8 %), and this did not meet the pre-study threshold for success.  The median PFS for the 2 groups was 2.6 months and 1.9 months, respectively.  The median overall survival (OS) for the 2 groups was 6.3 months and 3.9 months, respectively.  At least 1 AE of grade greater than or equal to 3 was observed in 75.5 % of the VEGFi-naive patients and in 73.9 % of the prior VEGFi patients.  The limited activity of sorafenib and temsirolimus at the dose and schedule used in the current study was observed with considerable toxicity of grade greater than or equal to 3; significant dose reductions that were needed in this treatment combination compared with tolerated single-agent doses may have contributed to the lack of efficacy.


UpToDate reviews on “Systemic therapy for advanced cholangiocarcinoma” (Stuart, 2015), “Treatment of localized cholangiocarcinoma: Adjuvant and neoadjuvant therapy and prognosis” (Anderson and Stuart, 2015a), and “Treatment options for locally advanced cholangiocarcinoma” (Anderson and Stuart, 2015b) do not mention temsirolimus as a therapeutic option.

Furthermore, NCCN’s Drugs & Biologics Compendium (2015) does not list cholangiocarcinoma as a recommended indication of temsirolimus.

Colorectal Cancer

Kaneko and associates (2014) stated that temsirolimus (TEM) has shown activity against a wide range of cancers in pre-clinical models, but its efficacy against colorectal cancer (CRC) has not been fully explored. These researchers evaluated the anti-tumor effect of TEM in CRC cell lines (CaR-1, HT-29, Colon26) in-vitro and in-vivo. In-vitro, cell growth inhibition was assessed using a MTS assay. Apoptosis induction and cell cycle effects were measured using flow cytometry. Modulation of mTOR signaling was measured using immunoblotting. Anti-tumor activity as a single agent was evaluated in a mouse subcutaneous tumor model of CRC. The effects of adding chloroquine, an autophagy inhibitor, to TEM were evaluated in-vitro and in-vivo. In-vitro, TEM was effective in inhibiting the growth of 2 CRC cell lines with highly activated AKT, possibly through the induction of G1 cell cycle arrest via a reduction in cyclin D1 expression, whereas TEM reduced HIF-1α and VEGF in all 3 cell lines. In a mouse subcutaneous tumor model, TEM inhibited the growth of tumors in all cell lines, not only through direct growth inhibition but also via an anti-angiogenic effect. These investigators also explored the effects of adding chloroquine, an autophagy inhibitor, to TEM. Chloroquine significantly potentiated the anti-tumor activity of TEM in-vitro and in-vivo. Moreover, the combination therapy triggered enhanced apoptosis, which corresponded to an increased Bax/Bcl-2 ratio. The authors concluded that based on these data, they proposed TEM with or without chloroquine as a new treatment option for CRC.

He et al (2016) stated that the mTOR is commonly activated in colon cancer; mTOR complex 1 (mTORC1) is a major down-stream target of the PI3K/ATK pathway and activates protein synthesis by phosphorylating key regulators of messenger RNA translation and ribosome synthesis. Rapamycin analogs everolimus and temsirolimus are non-ATP-competitive mTORC1 inhibitors, and suppress proliferation and tumor angiogenesis and invasion. These researchers showed that apoptosis plays a key role in their anti-tumor activities in colon cancer cells and xenografts through the DR5, FADD and caspase-8 axis, and is strongly enhanced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and 5-fluorouracil. The induction of DR5 by rapalogs is mediated by the ER stress regulator and transcription factor CHOP, but not the tumor suppressor p53, on rapid and sustained inhibition of 4E-BP1 phosphorylation, and attenuated by eIF4E expression. ATP-competitive mTOR/PI3K inhibitors also promote DR5 induction and FADD-dependent apoptosis in colon cancer cells. The authors concluded that these results established that activation of ER stress and the death receptor pathway as a novel anti-cancer mechanism of mTOR inhibitors.

NCCN’s Drugs & Biologics Compendium (2015) does not list colorectal cancer as a recommended indication of temsirolimus.

Head and Neck Squamous Cell Carcinoma

Nguyen et al (2012) noted that head and neck squamous cell carcinomas (HNSCC) represent 6 % of all cancers diagnosed each year in the United States, affecting approximately 43,000 new patients and resulting in approximately 12,000 deaths. Currently, 3 main rapalogs exist for the treatment of cancer: CCI-779 (temsirolimus), RAD001 (everolimus), and AP235373 (deforolimus). Clinicians managing HNSCC need to be aware of the 3 rapalogs. Extensive evidence has shown rapamycin-analogs to be effective agents in the treatment of a number of solid tumors. While extensive pre-clinical data suggested that HNSCC would be an appropriate tumor type to benefit from inhibition of the mTOR pathway, limited clinical data is yet available to support this. Numerous phase II trials evaluating mTOR inhibitors for use in HNSCC are currently recruiting patients.

Grunwald et al (2015) stated that HNSCC is a common disease, which has a poor prognosis after failure of therapy. Activation of the PI3K-AKT-mTOR axis is commonly detected in recurrent or metastatic HNSCC, and provided the rationale for the clinical phase II trial in pre-treated HNSCC. The primary end-point was the PFS rate (PFR) at 12 weeks. A total of 40 eligible patients have been recruited after failure of platinum chemotherapy and cetuximab. A pre-planned futility analysis was successfully passed after greater than or equal to 1 success was detected in 20 patients. Secondary objectives consisted of PFS, disease control rate (DCR), OS, safety and tolerability, and predictive biomarkers for KRAS, BRAF, PIK3CA mutations, and HPV status. Archived tumor tissue was analyzed for DNA sequence. A total of 40 patients were eligible. The PFR at 12 weeks was 40 % (95 % CI: 25.0 to 54.6). The median PFS and OS were 56 days (95 % CI: 36 to 113 days) and 152 days (76 to 256 days), respectively. In 33 assessable patients, disease stabilization occurred in 57.6 %, with tumor shrinkage in 13 patients (39.4 %). Overall, the treatment was well-tolerated. Fatigue (47.5 %), anemia (25.0 %), nausea (20.0 %), and pneumonia (20.0 %) were the most common adverse events. Neither PIK3CA mutations, nor HPV status were predictive for success with temsirolimus treatment. No mutations were found for KRAS or BRAF. The authors concluded that tumor shrinkage and efficacy parameter indicated that inhibition of the PI3K-AKT-mTOR axis was a putative novel treatment paradigm for SCCHN. These investigators could not identify parameters predictive for treatment success of temsirolimus, which underscored the need for refinement of the molecular analysis in future studies.

NCCN’s Drugs & Biologics Compendium (2015) does not list melanoma as a recommended indication of temsirolimus.

Hepato-Cellular Carcinoma

Yeo et al (2015) stated that the oncogenic PI3K/Akt/mTOR pathway is frequently activated in hepato-cellular carcinoma (HCC). Data on the mTOR inhibitor, temsirolimus, is limited in HCC patients with concomitant chronic liver disease. The objectives of this study were:
  1. In phase I, to determine dose-limiting toxicities (DLTs) and MTD of temsirolimus in HCC patients with chronic liver disease;
  2. In phase II, to assess activity of temsirolimus in HCC, and
  3. to explore potential biomarkers for response.

Major eligibility criteria included histologically confirmed advanced HCC and adequate organ function. In Phase I part of the study, temsirolimus was given weekly in 3-weekly cycle; dose levels were 20 mg (level 1), 25 mg (level 2) and 30 mg (level 3). The MTD was used in the subsequent phase II part; the primary end-point was PFS and secondary end-points were response and OS. In addition, exploratory analysis was conducted on pre-treatment tumor tissues to determine stathmin, pS6, pMTOR or p-AKT expressions as potential biomarkers for response; OS and PFS were calculated using the Kaplan-Meier method. Re-assessment CT scans were done every 6 weeks. All adverse events were reported using CTCAE v3. The Phase I part consisted of 19 patients, 2 of 6 patients at level 3 experienced DLT; dose level 2 was determined to be the MTD. The phase II part consisted of 36 patients. Among 35 assessable patients, there were 1 PR, 20 SD, and 14 progressive disease (PD). Overall, the median PFS was 2.83 months (95 % CI: 1.63 to 5.24). The median OS was 8.89 months (95 % CI: 5.89 to 13.30). Grade greater than or equal to 3 that occurred in more than 10 % of patients included thrombocytopenia (n = 4) and hyponatremia (n = 4). Exploratory analysis revealed that disease stabilization (defined as CR + PR + SD greater than 12 weeks) in tumors having high and low pMTOR H-scores to be 70 % and 29 %, respectively (OR 5.667, 95 % CI: 1.129 to 28.454, p = 0.035). The authors concluded that in HCC patients with chronic liver disease, the MTD of temsirolimus was 25 mg weekly in a 3-week cycle. The targeted PFS end-point was not reached. However, further studies to identify appropriate patient subgroup are needed.

Knox et al (2015) noted that there is strong rationale to combine temsirolimus (TEM) with bevacizumab (BEV) for patients with advanced HCC. These researchers performed a modified 2-stage Simon phase II trial with plans to advance to stage 2 if more than 2 patients had confirmed PR or more than 18 patients were progression free at 6 months out of 25 in stage 1. Toxicity, PFS and OS were secondary end-points. Eligible patients had advanced HCC, Child Pugh A liver status and no prior systemic therapy involving the VEGF or m-TOR targeted agents. Patients were treated with temsirolimus 25 mg I.V. on Days 1, 8, 15, and 22 of a 28-day cycle and bevacizumab 10 mg/kg I.V. on Days 1 and 15 of the cycle. A total of 28 eligible patients were enrolled, 26 evaluable receiving a median of 6.5 cycles (range of 1 to 18). Drug related toxicities were common including cytopenia, fatigue, mucositis, diarrhea and mild bleeds. Dose reductions or discontinuation of TEM were common. Accrual closed for presumed futility after interim analysis of the first 25 evaluable patients showed only 1 PR and 16/25 were progression-free at 6 months. However, the final data update in March 2013 demonstrated 4 confirmed PRs, a 5th unconfirmed PR and 16 /26 progression-free at 6 months. Median PFS and OS were 7 and 14 months, respectively. The authors concluded that this first-line HCC trial evaluating the BEV/TEM doublet reported an ORR of 19 % and OS of 14 months, which is favorable but requires further study at a more optimized dose and schedule.

Lung Cancer

The targeted therapies dabrafenib and neratinib are being tested separately in subsets of patients with BRAF- and HER2-mutant non-small cell lung cancer (NSCLC). While dabrafenib showed some promise, the preliminary results for neratinib with or without temsirolimus were insufficient to determine whether patients may benefit (No authors listed, 2014).

Ushijima et al (2015) noted that the mTOR correlates with cell survival under hypoxia and regulates hypoxia-inducible factor-1α (HIF-1α), a key protein in hypoxia-related events. However, the role of mTOR in radio-resistance has not been fully investigated. Therefore, the effect of mTOR on the radio-resistance of cancer cells under hypoxia was evaluated using the mTOR inhibitor temsirolimus. Clonogenic survival was examined in the A549 human lung adenocarcinoma cell line under normoxia or hypoxia, with or without temsirolimus. An oxygen enhancement ratio (OER) was calculated using the D(10) values, the doses giving 10 % survival. Western blotting was performed to investigate the effect of temsirolimus on mTOR and the HIF-1α pathway under normoxia and hypoxia. A549 cells showed a radio-resistance of 5.1 and 14.2 Gy, as indicated by D(10) values under normoxia and hypoxia, respectively; the OER was 2.8. The cell survival rates under hypoxia and with temsirolimus remarkably decreased compared with those under normoxia. The D(10) values of the cells under normoxia and hypoxia were 4.8 and 5.4 Gy, respectively (OER = 1.1). mTOR expression was suppressed by temsirolimus under both normoxia and hypoxia. HIF-1α expression decreased under hypoxia in the presence of temsirolimus. The authors concluded that these results suggested that temsirolimus can overcome the radio-resistance induced by hypoxia. They stated that when the fact that mTOR acts up-stream of HIF-1α is considered, these findings suggested that the restoration of radiation sensitivity by temsirolimus under hypoxia may be associated with the suppression of the HIF-1α pathway. Temsirolimus could therefore be used as a hypoxic cell radio-sensitizer.


Velho (2012) stated that melanoma is one of the most aggressive cancers, and it is estimated that 76,250 men and women will be diagnosed with melanoma of the skin in the USA in 2012. Over the last few decades many drugs have been developed but only in 2011 have new drugs demonstrated an impact on survival in metastatic melanoma. A systematic search of literature was conducted, and studies providing data on the effectiveness of current and/or future drugs used in the treatment of metastatic melanoma were selected for review. This review discussed the advantages and limitations of these agents, evaluating past, current and future clinical trials designed to overcome such limitations. The authors noted that “To date, there are 4 drugs approved by the Food and Drug Administration for melanoma (dacarbazine, interleukin-2, ipilimumab and vemurafenib). Despite efforts to develop new drugs, few of them have demonstrated any clinical benefits. Approved in 1975, dacarbazine remains the gold standard in chemotherapy, although ipilimumab and vemurafenib have raised many hopes in the last few years. Combining dacarbazine or other chemotherapy agents with new pharmacological agents may be a new way to achieve better clinical responses in patients with metastatic melanoma”. The authors concluded that advances in the molecular knowledge of melanoma have led to major improvements in the treatment of patients with metastatic melanoma, providing new targets and insights. However, heterogeneity among study populations, different approaches to treatment and the different melanoma types and localizations included in the trials made their comparison difficult; new studies focusing on drugs developed in recent decades are needed.

Vazakidou et al (2015) stated that the mTOR promotes cancer cell proliferation and survival, transduces pro-angiogenic signals and regulates immune cell differentiation and function. These researchers hypothesized that temsirolimus, an mTOR inhibitor, would curtail experimental mesothelioma progression in-vivo by limiting tumor cell growth, abrogating tumor angiogenesis and modulating immune/inflammatory tumor milieu. These investigators produced flank and pleural syngeneic murine mesotheliomas by delivering AE17 and AB1 murine mesothelioma cells into the right flank or the pleural space of C57BL/6 and BALB/c mice, respectively. Animals were given 5 times/week intra-peritoneal injections of 20 mg/kg temsirolimus or vehicle and were sacrificed on day 26 (flank) or on day 15 (pleural) post-tumor cell propagation. Temsirolimus limited mesothelioma growth in-vivo by stimulating tumor cell apoptosis, inhibiting tumor angiogenesis, enhancing tumor lymphocyte abundance and blocking pro-tumor myeloid cell recruitment. Pleural fluid accumulation was significantly mitigated in AE17 but not in AB1 mesotheliomas. In-vitro, temsirolimus hindered mesothelioma cell growth, NF-kappaB activation and macrophage migration. The authors concluded that temsirolimus apart from inducing tumor cell apoptosis, targets tumor angiogenesis and influences inflammatory tumor microenvironment to halt experimental mesothelioma growth in-vivo.

NCCN’s Drugs & Biologics Compendium (2015) does not list melanoma as a recommended indication of temsirolimus.


Zhao et al (2015) noted that the insulin-like growth factors (IGFs), IGF-1 and IGF-2, have been implicated in the growth, survival and metastasis of a broad range of malignancies including pediatric tumors. They bind to the IGF receptor type 1 (IGF-1R) and the insulin receptor (IR) which are over-expressed in many types of solid malignancies. Activation of the IR by IGF-2 results in increased survival of tumor cells. These researchers have previously identified a novel human monoclonal antibody, m708.5, which binds with high (pM) affinity to both human IGF-1 and IGF-2, and potently inhibits phosphorylation of the IGF-1R and the IR in tumor cells. m708.5 exhibited strong anti-tumor activity as a single agent against most cell lines derived from neuroblastoma, Ewing family of tumor, rhabdomyosarcoma and osteosarcoma. When tested in neuroblastoma cell lines, it showed strong synergy with temsirolimus and synergy with chemotherapeutic agents in-vitro. In xenograft models, the combination of m708.5 and temsirolimus significantly inhibited neuroblastoma growth and prolonged mouse survival. Taken together, these results support the clinical development of m708.5 for pediatric solid tumors with potential for synergy with chemotherapy and mTOR inhibitors.

Neuroendocrine Tumors

Chan and Kulke (2014) stated that neuroendocrine tumors (NETs) are a heterogeneous group of malignancies characterized by variable but most often indolent biologic behavior. Well-differentiated NETs can be broadly classified as either carcinoid or pancreatic NET. Although they have similar characteristics on routine histologic evaluation, the 2 tumor subtypes have different biology and respond differently to treatment, with most therapeutic agents demonstrating higher response rates in pancreatic NETs compared with carcinoid. Until recently, systemic treatment options for patients with advanced NETs were limited. However, improvements in the understanding of signaling pathways involved in the pathogenesis, growth, and spread of NETs have translated into an expansion of treatment options. Aberrant signaling through the mTOR pathway has been implicated in neuroendocrine tumorigenesis. Additionally, altered expression of mTOR pathway components has been observed in NETs and has been associated with clinical outcomes. Targeting the mTOR pathway has emerged as an effective treatment strategy in the management of advanced NETs. In a randomized, placebo-controlled study of patients with advanced pancreatic NET, treatment with the mTOR inhibitor everolimus was associated with improved PFS. Largely based upon these data, everolimus has been approved in the United States and Europe for the treatment of patients with advanced pancreatic NET. The activity of everolimus remains under investigation in patients with carcinoid tumors. In a randomized study of patients with advanced carcinoid tumors associated with carcinoid syndrome, the addition of everolimus to octreotide was associated with improved PFS compared with octreotide. However, the results did not meet the pre-specified level of statistical significance based on central review of radiographic imaging. Results from a randomized study examining the efficacy of everolimus in patients with non-functional gastro-intestinal and lung NETs are awaited. In addition, further investigation is needed to determine whether primary tumor site or other clinical and molecular factors can impact response to mTOR inhibition. Although everolimus can slow tumor progression, significant tumor reduction is rarely obtained. Targeting multiple signaling pathways is a treatment strategy that may provide better tumor control and overcome resistance mechanisms involved with targeting a single pathway. Results of ongoing and future studies will provide important information regarding the added benefit of combining mTOR inhibitors with other targeted agents, such as VEGF pathway inhibitors, and cytotoxic chemotherapy in the treatment of advanced NETs.

Hobday et al (2015) stated that there are few effective therapies for pancreatic neuroendocrine tumors (PNETs). Recent placebo-controlled phase III trials of the mTOR inhibitor everolimus and the vascular endothelial growth factor (VEGF)/platelet-derived growth factor receptor inhibitor sunitinib have noted improved PFS. Pre-clinical studies have suggested enhanced anti-tumor effects with combined mTOR and VEGF pathway-targeted therapy. These investigators conducted a clinical trial to evaluate combination therapy against these targets in PNETs. They conducted a 2-stage, single-arm, phase II trial of the mTOR inhibitor temsirolimus 25 mg intravenously (IV) once-weekly and the VEGF-A monoclonal antibody bevacizumab 10 mg/kg IV once every 2 weeks in patients with well or moderately differentiated PNETs and progressive disease by RECIST within 7 months of study entry. Co-primary end-points were tumor response rate and 6-month PFS. A total of 58 patients were enrolled, and 56 patients were eligible for response assessment. Confirmed response rate (RR) was 41 % (23 of 56 patients); PFS at 6 months was 79 % (44 of 56). Median PFS was 13.2 months (95 % CI: 11.2 to 16.6). Median OS was 34 months (95 % CI: 27.1 to not reached). For evaluable patients, the most common grade 3 to 4 adverse events attributed to therapy were hypertension (21 %), fatigue (16 %), lymphopenia (14 %), and hyperglycemia (14 %). The authors concluded that the combination of temsirolimus and bevacizumab had substantial activity and reasonable tolerability in a multi-center phase II clinical trial, with RR of 41 %, well in excess of single targeted agents in patients with progressive PNETs. Six-month PFS was a notable 79 % in a population of patients with disease progression by RECIST criteria within 7 months of study entry. The authors concluded that on the basis of this phase II clinical trial, continued evaluation of combination mTOR and VEGF pathway inhibitors is needed.

NCCN’s Drugs & Biologics Compendium (2015) does not list neuroendocrine tumors as recommended indications of temsirolimus.

Ovarian Cancer

Matsumoto et al (2015) noted that several “lines of therapy” that utilize cytotoxic agents and are driven by platinum-free intervals are the current standard of care for patients with recurrent ovarian cancer. For patients with platinum-resistant disease, single-agent chemotherapy (pegylated liposomal doxorubicin, topotecan, gemcitabine or weekly paclitaxel) is the standard of care. For patients with platinum-sensitive disease, combination chemotherapy (carboplatin plus paclitaxel, pegylated liposomal doxorubicin or gemcitabine) is the standard of care. In addition, anti-angiogenic therapy using bevacizumab is an established option. Future directions could include “lines of therapy” with biologic agents driven by specific biologic targets. Data from anti-angiogenic agents (trebananib, pazopanib and cediranib), anti-folate drugs (farletuzumab and vintafolide), poly(ADP-ribose) polymerase inhibitors (olaparib and veliparib), mTOR inhibitors (everolimus and temsirolimus) and immune-editing agents (nivolumab) had been summarized in this review.

NCCN’s Drugs & Biologics Compendium (2015) does not list ovarian cancer as a recommended indication of temsirolimus.

Other Solid Tumors

Piatek (2014) determined the MTD of the combination of weekly temsirolimus and every other week vinorelbine in patients with advanced or refractory solid tumors. Patients were treated with I.V. temsirolimus on days 1, 8, 15, and 22 and I.V. vinorelbine on days 1 and 15. Cycles were repeated every 28 days. A total of 19 patients were enrolled in the study. Tumor types included lung (n = 5), prostate (n = 2), neuroendocrine of pancreas (n = 1), bladder (n = 2), uterus (n = 3), cervix (n = 4), and vagina (n = 2). All patients had received prior chemotherapy. Four patients were enrolled to dose level I, 9 to dose level II, and 6 to dose level III. Six patients were non-evaluable and replaced; 57 total cycles were administered. There was 1 DLT at level II (grade 3 anorexia/dehydration) and 2 at level III (grade 3 hypokalemia; grade 4 neutropenia). Two patients died at dose level III; 1 was study-related with grade 4 neutropenia. Grade 3/4 toxicities observed during the first cycle included neutropenia (n = 2), anemia (n = 1), anorexia (n = 1), dehydration (n = 1), hyperglycemia (n = 1), hypertriglyceridemia (n = 1), and hypokalemia (n = 1). Best response included 2 patients (prostate cancer and NSCLC) with PR and 8 patients with SD with median duration of best response of 3.2 months. The authors concluded that temsirolimus 25 mg given days 1, 8, 15, and 22 in combination with vinorelbine 20 mg/m(2) given days 1 and 15 every 4 weeks was found to be the MTD. This dose combination is considered feasible in phase II trials.

Rangwala and colleagues (2014) stated that the combination of TEM and hydroxychloroquine (HCQ), an autophagy inhibitor, augments cell death in pre-clinical models. This phase 1 dose-escalation study evaluated the MTD, safety, preliminary activity, pharmacokinetics, and pharmacodynamics of HCQ in combination with TEM in cancer patients. In the dose escalation portion, 27 patients with advanced solid malignancies were enrolled, followed by a cohort expansion at the top dose level in 12 patients with metastatic melanoma. The combination of HCQ and TEM was well-tolerated, and grade 3 or 4 toxicity was limited to anorexia (7 %), fatigue (7 %), and nausea (7 %). An MTD was not reached for HCQ, and the recommended phase II dose was HCQ 600 mg twice-daily in combination with TEM 25 mg weekly. Other common grade 1 or 2 toxicities included fatigue, anorexia, nausea, stomatitis, rash, and weight loss. No responses were observed; however, 14/21 (67 %) patients in the dose escalation and 14/19 (74 %) patients with melanoma achieved SD. The median PFS in 13 melanoma patients treated with HCQ 1,200 mg/day in combination with TEM was 3.5 months. Novel 18-fluorodeoxyglucose positron emission tomography (FDG-PET) measurements predicted clinical outcome and provided further evidence that the addition of HCQ to TEM produced metabolic stress on tumors in patients that experienced clinical benefit. Pharmacodynamic evidence of autophagy inhibition was evident in serial PBMC and tumor biopsies only in patients treated with 1,200 mg daily HCQ. The authors concluded that the findings of this study indicated that TEM and HCQ is safe and tolerable, modulated autophagy in patients, and had significant anti-tumor activity. They stated that further studies combining mTOR and autophagy inhibitors in cancer patients are needed.

Acute Lymphoblastic Leukemia

In a phase I clinical trial, Rheingold and colleagues (2017) noted that the phosphatidylinositol 3-kinase (PI3K)/mTOR signaling pathway is commonly dysregulated in acute lymphoblastic leukemia (ALL).  These researchers studied the use of temsirolimus in combination with UKALL R3 re-induction chemotherapy in children and adolescents with second or greater relapse of ALL.  The initial temsirolimus dose level (DL1) was 10 mg/m2 weekly × 3 doses.  Subsequent patient cohorts received temsirolimus 7.5 mg/m2 weekly × 3 doses (DL0) or, secondary to toxicity, 7.5 mg/m2 weekly × 2 doses (DL-1).  A total of 16 patients were enrolled, 15 were evaluable for toxicity; DLT occurred at all 3 dose levels and included hyper-triglyceridemia, mucositis, ulceration, hypertension with reversible posterior leucoencephalopathy, elevated gamma-glutamyltransferase or alkaline phosphatase and sepsis.  The addition of temsirolimus to UKALL R3 re-induction therapy resulted in excessive toxicity and was not tolerable in children with relapsed ALL.  However, this regimen induced remission in 7 of 15 patients; 3 patients had minimal residual disease levels of less than 0.01 %.  The authors concluded that inhibition of PI3K signaling was detected in patients treated at all dose levels of temsirolimus, but inhibition at an early time-point did not appear to correlate with clinical responses at the end of re-induction therapy.  These preliminary findings need to be further investigated in phase II/III clinical trials.

Myelodysplastic Syndromes

Wermke and colleagues (2016) noted that the mTOR pathway integrates various pro-proliferative and anti-apoptotic stimuli and is involved in regulatory T-cell (TREG) development.  As these processes contribute to the pathogenesis of myelodysplastic syndromes (MDS), these investigators hypothesized that mTOR modulation with temsirolimus (TEM) might show activity in MDS.  This prospective multi-center trial enrolled lower and higher risk MDS patients, provided that they were transfusion-dependent/neutropenic or relapsed/refractory to 5-azacitidine, respectively.  All patients received TEM at a weekly dose of 25-mg.  Of the 9 lower- and 11 higher-risk patients included, only 4 (20 %) reached the response assessment after 4 months of treatment and showed SD without hematological improvement.  The remaining patients discontinued TEM prematurely due to adverse events (AEs).  Median OS was not reached in the lower-risk group and 296 days in the higher-risk group.  These researchers observed a significant decline of bone marrow (BM) vascularization (p = 0.006) but were unable to demonstrate a significant impact of TEM on the balance between TREG and pro-inflammatory T-helper-cell subsets within the peripheral blood or BM.  The authors concluded that mTOR-modulation with TEM at a dose of 25 mg/week was accompanied by considerable toxicity and had no beneficial effects in elderly MDS patients.

Parkinson's Disease

Siracusa and colleagues (2018) stated that Parkinson's disease (PD) is a disorder caused by degeneration of dopaminergic neurons.  At the moment, there is no cure.  Recent studies have shown that autophagy may have a protective function against the advance of a number of neurodegenerative diseases.  Temsirolimus is an analogue of rapamycin that induces autophagy by inhibiting mTOR complex 1.  In the present study, these researchers examined the neuroprotective effects of temsirolimus (5 mg/kg intraperitoneal) on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced (MPTP) neurotoxicity in in-vivo model of PD.  At the end of the experiment, brain tissues were processed for histological, immunohistochemical, Western blot, and immunofluorescent analysis.  Treatment with temsirolimus significantly ameliorated behavioral deficits, increased the expression of specific markers of PD such as tyrosine hydroxylase, dopamine transporter, as well as decreased the up-regulation of α-synuclein in the substantia nigra after MPTP induction.  Furthermore, Western blot and immunohistochemistry analysis showed that temsirolimus administration significantly increased autophagy process.  In fact, treatment with temsirolimus maintained high Beclin-1, p62, and microtubule-associated protein 1A/1B-light chain 3 expression and inhibited the p70S6K expression.  In addition, these investigators showed that temsirolimus also exhibited anti-inflammatory properties as indexed by the significant inhibition of the expression of mitogen-activated protein kinases such as p-JNK, p-p38, and p-ERK, and the restored levels of neurotrophic factor expression such as BDNF and NT-3.  On the basis of this evidence, these researchers demonstrated that temsirolimus was able to modulate both the autophagic process and the neuroinflammatory pathway involved in PD, actions which may underlie its neuroprotective effect.

Primary CNS Lymphoma

In a phase II clinical trial, Korfel and colleagues (2016) examined the effectiveness of temsirolimus in patients with relapsed or refractory primary CNS lymphoma (PCNSL).  Immunocompetent adults with histologically confirmed PCNSL after experiencing high-dose methotrexate-based chemotherapy failure who were not eligible for or had experienced high-dose chemotherapy with autologous stem-cell transplant (ASCT) failure were included.  The first cohort (n = 6) received 25 mg temsirolimus intravenously once-weekly.  All consecutive patients received 75 mg intravenously once-weekly.  A total of 37 eligible patients (median age of 70 years) were included whose median time since their last treatment was 3.9 months (range of 0.1 to 14.6 months); CR was seen in 5 patients (13.5 %), CR unconfirmed in 3 (8%), and PR in 12 (32.4 %) for an ORR of 54 %.  Median PFS was 2.1 months (95 % CI: 1.1 to 3.0 months).  The most frequent Common Toxicity Criteria greater than or equal to 3° AE was hyperglycemia in 11 (29.7 %) patients, thrombocytopenia in 8 (21.6 %), infection in 7 (19 %), anemia in 4 (10.8 %), and rash in 3 (8.1 %); 14 blood/CSF pairs were collected in 9 patients (10 pairs in 5patients in the 25-mg cohort and 4 pairs in 4 patients in the 75-mg cohort).  The mean maximum blood concentration was 292 ng/ml for temsirolimus and 37.2 ng/ml for its metabolite sirolimus in the 25-mg cohort and 484 ng/ml and 91.1 ng/ml, respectively, in the 75-mg cohort.  Temsirolimus CSF concentration was 2 ng/ml in 1 patient in the 75-mg cohort; in all others, no drug was found in their CSF.  The authors concluded that single-agent temsirolimus at a weekly dose of 75 mg was found to be active in relapsed/refractory patients with PCNSL; however, responses were usually short-lived. 

These investigators stated that frequent administration of steroids before response assessment had to be considered a confounding factor for response evaluation due to their lymphotoxic effect, which may persist for several weeks after discontinuation.  Only in 7 of 20 responders not taking steroids for at least 3 months before 1st response assessment could the therapeutic effect be attributed solely to temsirolimus.  Another drawback was the preferential inclusion of elderly patients whose initial treatment was frequently not according to the current standards used in younger patients.  Generalization of these findings to unselected patients with PCNSL should thus be viewed with caution.  The authors noted that although most responses were short-lived, some patients achieved long-term control.  They stated that further evaluation in combination with other drugs appeared reasonable.

Thyroid Cancer

In a single-institution, phase II clinical trial, Sherman and colleagues (2017) stated that patients with recurrent and/or metastatic, radioactive iodine-refractory thyroid carcinoma have limited therapeutic options.  Sorafenib, an oral kinase inhibitor, is approved by the FDA for the treatment of radioactive iodine-refractory thyroid carcinoma, although it demonstrated low response rates (12.2 %) as a single-agent in the 1st-line setting.  The objective of the current study was to examine if adding the mammalian target of rapamycin inhibitor temsirolimus to sorafenib could improve on these results.  A total of 36 patients with metastatic, radioactive iodine-refractory thyroid carcinoma of follicular origin received treatment with the combination of oral sorafenib (200 mg twice-daily) and intravenous temsirolimus (25 mg weekly).  The receipt of prior systemic treatment with cytotoxic chemotherapy and targeted therapy, including sorafenib, was permitted.  The primary end-point was the radiographic response rate.  The best response was a PF in 8 patients (22 %), SD in 21 (58 %), and PD in 1 (3 %); 6 patients were not evaluable for a response.  Patients who had received any prior systemic treatment had a response rate of 10 % compared with 38 % of those who had not received prior systemic treatment; 1 of 2 patients with anaplastic thyroid cancer had an objective response.  The PFS rate at 1 year was 30.5 %.  The most common grade 3 and 4 toxicities associated with sorafenib and temsirolimus included hyperglycemia, fatigue, anemia, and oral mucositis.  The authors concluded that sorafenib and temsirolimus appeared to be an active combination in patients with radioactive iodine-refractory thyroid carcinoma, especially in patients who received no prior treatment compared with historic data from single-agent sorafenib.  Activity was also observed in patients who previously received sorafenib.  These investigators stated that this regimen warrants further investigation.

Bladder Cancer

Pulido and colleagues (2018) noted that bladder cancer is the 7th cause of death from cancer in men and 10th in women.  Metastatic patients have a poor prognosis with a median OS of 14 months.  Until recently, vinflunine was the only 2nd-line chemotherapy available for patients who relapse.  Deregulation of the PI3K/AKT/mTOR pathway was observed in more than 40 % of bladder tumors and suggested the use of mTOR as a target for the treatment of urothelial cancers.  This trial assessed the efficacy of temsirolimus in a homogenous cohort of patients with recurrent or metastatic bladder cancer following 1st-line chemotherapy.  Efficacy was measured in terms of non-progression at 2 months according to the RECIST v1.1 criteria.  Based on a 2-stage optimal Simon's design, 15 non-progressions out of 51 evaluable patients were required to claim efficacy.  Patients were treated at a weekly dose of 25 mg IV until progression, unacceptable toxicities or withdrawal.  Among the 54 patients enrolled in the study between November 2009 and July 2014, 45 were assessable for the primary efficacy end-point.  A total of 22 (48.9 %) non-progressions were observed at 2 months with 3 PRs and 19 SD.  Remarkably, 4 patients were treated for more than 30 weeks.  A total of 50 patients experienced at least a related grade1/2 (94 %) and 28 patients (52.8 %) a related grade 3/4 AE; 11 patients had to stop treatment for toxicity.  This led to recruitment being halted by an independent data monitoring committee with regard to the risk-benefit balance and the fact that the primary objective was already met.  The authors concluded that while the positivity of this trial indicated a potential benefit of temsirolimus for a subset of bladder cancer patients who are refractory to 1st-line platinum-based chemotherapy, the risk of AEs associated with the use of this mTOR inhibitor would need to be considered when such an option is envisaged in this frail population of patients.  It also remains to identify patients who will benefit the most from this targeted therapy.

Desmoplastic Small Round Cell Tumor

Tarek and co-workers (2018) stated that desmoplastic small round cell tumor (DSRCT) is a rare mesenchymal tumor that typically presents with multiple abdominal masses.  Initial treatment is multi-modal in nature.  Patients with relapsed DSRCT have a poor prognosis, and there are no standard therapies.  These investigators reported their experience with 5 patients treated with vinorelbine, cyclophosphamide, and temsirolimus (VCT).  Median number of VCT courses delivered was 7 (range of 4 to 14 courses), and PR was observed in all patients.  Median time to progression or relapse was 8.5 months (range of 7 to 16 months).  Neutropenia and mucositis were most common toxicities (n = 4 each).  Moreover, they stated that further study is needed to determine if this regimen can be utilized in newly diagnosed patients, and additional pre-clinical study is needed to determine the mechanism of action for this combination in DSRCT.  The authors noted that one drawback of this report was that they were unable to determine if the observed responses were due to a synergistic effect derived from this drug combination versus single agent activity.

Pancreatic Cancer

Hajatdoost and colleagues (2018) stated that pancreatic cancer is one of the most fatal cancers. Cytotoxic chemotherapy remains the mainstream treatment for unresectable pancreatic cancer. In a systematic review, these researchers compared the OS and PFS outcomes obtained from recent phase-II and phase-III clinical trials of pancreatic cancer chemotherapy. A total of 32 studies were included and compared based on chemotherapy agents or combinations used. Additionally, outcomes of 1st-line versus 2nd-line chemotherapy in pancreatic cancer were compared. In studies that examined the treatments in adjuvant settings, the highest OS reported was for S-1 in patients, who received prior surgical resection (46.5 months). In neoadjuvant settings, the combination of gemcitabine, docetaxel, and capecitabine prior to the surgical resection had promising outcomes (OS of 32.5 months). In non-adjuvant settings, the highest OS reported was for the combination of temsirolimus plus bevacizumab (34.0 months). Among studies that examined 2nd-line treatment, the highest OS reported was for the combination of gemcitabine plus cisplatin (35.5 months), then temsirolimus plus bevacizumab (34.0 months). The authors concluded that there is a need to develop further strategies besides chemotherapy to improve the outcomes in pancreatic cancer treatment. They stated that future studies should consider surgical interventions, combination chemotherapy, and individualized 2nd-line treatment based on the prior chemotherapy.

Karavasilis and associates (2018) determined the MTD and DLTs of a novel gemcitabine (G) and temsirolimus (T) combination (phase-I) and estimated the 6-month PFS in patients treated with the T + G combination (phase-II). Eligible patients with histologically confirmed inoperable or metastatic pancreatic carcinoma (MPC) were entered into the trial; G was given bi-weekly and T weekly in a 4-week cycle. The 1st dose level was set at G 800 mg/m2 and T 10 mg; G was escalated in increments of 200 mg/m2 and T in increments of 5 mg until DLT was reached, and the recommended dose was used for the phase-II part. A total of 30 patients were enrolled in the phase-I component at the pre-planned 6 dose levels; 1 bilirubin DLT of grade-III occurred at the 1st dose level. The MTD was established as the approved doses of both drugs. A total of 55 patients were entered into the phase-II component. Median relative dose intensities administered in the 1st cycle were 0.75 for T and 0.99 for G. Grade 3 to 4 hematological toxicities were recorded in 87.3 % of patients. The most common non-hematological AEs were metabolic disorders (81.8 %) followed by gastro-intestinal (GI) disorders (63.6 %). Median PFS was 2.69 months (95 % CI: 1.74 to 4.95) and median OS was 4.95 months (95 % CI: 3.54 to 6.85), while the 6-month PFS rate was 30.9 %. The authors concluded that combination of G and T was feasible in patients with locally advanced or MPC with manageable side effects, but lacked clinical efficacy.


Chen and colleagues (2019) noted that targeting the mammalian target of rapamycin (mTOR) is a promising strategy for cancer therapy. Temsirolimus is a potent mTOR inhibitor. These investigators were the first to provide pre-clinical evidence that temsirolimus is an attractive candidate for retinoblastoma treatment as a dual inhibitor of retinoblastoma and angiogenesis. They showed that temsirolimus selectively inhibited growth, survival and migration of retinoblastoma cells while sparing normal retinal and fibroblast cells, with IC50 value that was within the clinically achievable range. Temsirolimus potently inhibited retinal angiogenesis via targeting biological functions of retinal endothelial cells. The authors’ mechanism analysis demonstrated that temsirolimus inhibited retinoblastoma and angiogenesis via suppressing mTOR signaling and secretion of pro-angiogenic cytokines. In line with in-vitro data, these researchers further demonstrated the inhibitory effects of temsirolimus on retinoblastoma and angiogenesis in in-vivo xenograft mouse model. The authors concluded that these findings provided a pre-clinical rationale to examine temsirolimus as a strategy to treat retinoblastoma and highlighted the therapeutic value of targeting mTOR in retinoblastoma.


Dosage Adjustments

  • Absolute neutrophil count less than 1000/mm³: hold until Grade 2 or less and then restart with a dose reduction of 5 mg/week; may continue reducing the dose until a dose no lower than 15 mg/week is reached.
  • Platelet count less than 75,000/mm³: hold until Grade 2 or less and then restart with a dose reduction of 5 mg/week; may continue reducing the dose until a dose no lower than 15 mg/week is reached.
  • Any Grade 3 or 4 adverse event: hold until Grade 2 or less and then restart with a dose reduction of 5 mg/week; may continue reducing the dose until a dose no lower than 15 mg/week is reached.
  • Concomitant strong CYP3A4 inhibitors (such as ketoconazole): avoid if possible or consider dose reduction of Torisel (temsirolimus) to 12.5 mg/week; allow for one week washout period if the CYP3A4 inhibitor is discontinued prior to increasing back to the original Torisel (temsirolimus) dose.
  • Concomitant strong CYP3A4 inducers (such as dexamethasone, rifampin): avoid if possible or consider dose increase of Torisel (temsirolimus) from 25 to 50 mg/week; return to original Torisel (temsirolimus) dose if CYP3A4 inducer is discontinued.
  • Renal impairment: no dosage adjustment necessary.
  • Member should avoid eating grapefruit or drinking grapefruit juice while taking this drug.
Table: CPT Codes / HCPCS Codes / ICD-10 Codes
Code Code Description

Information in the [brackets] below has been added for clarification purposes.   Codes requiring a 7th character are represented by "+":

Other CPT codes related to the CPB:

96409 Chemotherapy administration; intravenous, push technique, single or initial substance/drug
96413 - 96417 Chemotherapy administration; intravenous infusion technique

HCPCS codes covered if selection criteria are met:

J9330 Injection, temsirolimus, 1 mg (Torisel)

ICD-10 codes covered if selection criteria are met:

C49.8 - C49.9 Malignant neoplasm of connective and soft tissue
C54.1 Malignant neoplasm of endometrium
C64.1 - C65.9 Malignant neoplasm of kidney and renal pelvis
D49.2 Neoplasm of unspecified behavior of bone, soft tissue, and skin
J84.81 Lymphangioleiomyomatosis

ICD-10 codes not covered for indications listed in the CPB (not all-inclusive):

C25.0 - C25.9 Malignant neoplasm of pancreas
C69.20 - C69.22 Malignant neoplasm of retina
C73 Malignant neoplasm of thyroid gland
C83.30 - C83.39 Diffuse large B-cell lymphoma [primary CNS lymphoma]
C83.80 - C83.89 Other non-follicular lymphoma [primary CNS lymphoma]
C85.80 - C85.89 Other specified types of non-Hodgkin lymphoma [primary CNS lymphoma]
C91.0 - C91.02 Acute lymphoblastic leukemia (ALL)
D09.3 Carcinoma in situ of thyroid and other endocrine glands
D46.0 - D46.9 Myelodysplastic syndromes
D48.1 Malignant neoplasm of specified parts of peritoneum [Desmoplastic small round cell tumor]
G20 Parkinson’s disease

The above policy is based on the following references:

  1. Hudes  G, et al. Temsirolimus, Interferon Alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271-2281.
  2. Wyeth Pharmaceuticals, Inc. Torisel Kit (temsirolimus) injection, for intravenous use only. Prescribing Information.  Philadephia, PA: Wyeth Pharmaceuticals; revised May 2012.
  3. National Cancer Institute. Torisel, Cancer Topics. Bethesda, MD: NCI; updated October 28, 2011. Available at: www.cancer.gov/cancertopics/druginfo/temsirolimus. Accessed March 11, 2013.
  4. Torisel. Drug Facts and Comparisons. Facts & Comparisons [database online]. St. Louis, MO: Wolters Kluwer Health, Inc; updated periodically.
  5. National Comprehensive Cancer Network (NCCN). Kidney cancer. NCCN Clinical Practice Guidelines in Oncology v.1.2013. Fort Washington, PA: NCCN; 2013.
  6. National Comprehensive Cancer Network (NCCN). Uterine neoplasms. NCCN Clinical Pratice Guidelines in Oncology v.2.2015. Fort Washington, PA: NCCN, 2015. 
  7. National Comprehensive Cancer Network (NCCN). Soft tissue sarcoma. NCCN Clinical Practice Guidelines in Oncology v.1.2015. Fort Washington, PA: NCCN; 2015.
  8. Nguyen SA, Walker D, Gillespie MB, et al. mTOR inhibitors and its role in the treatment of head and neck squamous cell carcinoma. Curr Treat Options Oncol. 2012;13(1):71-81
  9. Velho TR. Metastatic melanoma - a review of current and future drugs. Drugs Context. 2012;2012:212242
  10. Liu W, Huang S, Chen Z, et al. Temsirolimus, the mTOR inhibitor, induces autophagy in adenoid cystic carcinoma: In vitro and in vivo. Pathol Res Pract. 2014;210(11):764-769
  11. Jiang T, Yu JT, Zhu XC, et al. Temsirolimus promotes autophagic clearance of amyloid-β and provides protective effects in cellular and animal models of Alzheimer's disease. Pharmacol Res. 2014;81:54-63
  12. Qiao L, Liang Y, Mira RR, et al. Mammalian target of rapamycin (mTOR) inhibitors and combined chemotherapy in breast cancer: A meta-analysis of randomized controlled trials. Int J Clin Exp Med. 2014;7(10):3333-3343
  13. Piha-Paul SA, Shin SJ, Vats T, et al. Pediatric patients with refractory central nervous system tumors: Experiences of a clinical trial combining bevacizumab and temsirolimus. Anticancer Res. 2014;34(4):1939-1945
  14. Wen PY, Chang SM, Lamborn KR, et al. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro Oncol. 2014;16(4):567-578
  15. Kaneko M, Nozawa H, Hiyoshi M, et al. Temsirolimus and chloroquine cooperatively exhibit a potent antitumor effect against colorectal cancer cells. J Cancer Res Clin Oncol. 2014;140(5):769-781
  16. No authors listed. Expanding targeted therapies for NSCLC. Cancer Discov. 2014;4(12):OF1
  17. Chan J, Kulke M. Targeting the mTOR signaling pathway in neuroendocrine tumors. Curr Treat Options Oncol. 2014;15(3):365-379
  18. Piatek CI, Raja GL, Ji L, et al.  Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors. Cancer Chemother Pharmacol. 2014;74(6):1227-1234. Autophagy. 2014;10(8):1391-1402
  19. Rangwala R, Chang YC, Hu J, et al. Combined MTOR and autophagy inhibition: Phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma
  20. Fenske TS, Shah NM, Kim KM, et al. A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study. Cancer. 2015;121(19):3465-3471
  21. Stuart KE. Systemic therapy for advanced cholangiocarcinoma. UpToDate [online serial]. Waltham, MA: UpToDate; reviewed August 2015
  22. Anderson CD, Stuart KE. Treatment of localized cholangiocarcinoma: Adjuvant and neoadjuvant therapy and prognosis. UpToDate [online serial]. Waltham, MA: UpToDate; reviewed August 2015a
  23. Anderson CD, Stuart KE. Treatment options for locally advanced cholangiocarcinoma. UpToDate [online serial]. Waltham, MA: UpToDate; reviewed August 2015b
  24. Grunwald V, Keilholz U, Boehm A, et al. TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO). Ann Oncol. 2015;26(3):561-567
  25. Yeo W, Chan SL, Mo FK, et al. Phase I/II study of temsirolimus for patients with unresectable hepatocellular carcinoma (HCC)- a correlative study to explore potential biomarkers for response. BMC Cancer. 2015;15:395
  26. Knox JJ, Qin R, Strosberg JR, et al. A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma. Invest New Drugs. 2015;33(1):241-246
  27. Ushijima H, Suzuki Y, Oike T, et al. Radio-sensitization effect of an mTOR inhibitor, temsirolimus, on lung adenocarcinoma A549 cells under normoxic and hypoxic conditions. J Radiat Res. 2015;56(4):663-668
  28. National Comprehensive Cancer Network (NCCN). Temsirolimus. NCCN Drugs & Biologics Compendium. Fort Washington, PA: NCCN; 2015.
  29. Zhao Q, Tran H, Dimitrov DS, Cheung NK. A dual-specific anti-IGF-1/IGF-2 human monoclonal antibody alone and in combination with temsirolimus for therapy of neuroblastoma. Int J Cancer. 2015;137(9):2243-2252
  30. Hobday TJ, Qin R, Reidy-Lagunes D, et al. Multicenter phase II trial of temsirolimus and bevacizumab in pancreatic neuroendocrine tumors. J Clin Oncol. 2015;33(14):1551-1556
  31. Matsumoto K, Onda T, Yaegashi N. Pharmacotherapy for recurrent ovarian cancer: Current status and future perspectives. Jpn J Clin Oncol. 2015;45(5):408-410
  32. Wagner LM, Fouladi M, Ahmed A, et al. Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2015;62(3):440-444
  33. Eroglu Z, Tawbi HA, Hu J, et al. A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas. Br J Cancer. 2015;112(10):1644-1651
  34. He K, Zheng X, Li M, et al. mTOR inhibitors induce apoptosis in colon cancer cells via CHOP-dependent DR5 induction on 4E-BP1 dephosphorylation. Oncogene. 2016;35(2):148-157.
  35. Vazakidou ME, Magkouta S, Moschos C, et al. Temsirolimus targets multiple hallmarks of cancer to impede mesothelioma growth in vivo. Respirology. 2015;20(8):1263-1271.
  36. National Comprehensive Cancer Network (NCCN). Temsirolimus. NCCN Drugs & Biologics Compendium. Fort Washington, PA: NCCN; 2016.
  37. Wermke M, Schuster C, Nolte F, et al. Mammalian-target of rapamycin inhibition with temsirolimus in myelodysplastic syndromes (MDS) patients is associated with considerable toxicity: Results of the temsirolimus pilot trial by the German MDS Study Group (D-MDS). Br J Haematol. 2016;175(5):917-924.
  38. Korfel A, Schlegel U, Herrlinger U, et al. Phase II trial of temsirolimus for relapsed/refractory primary CNS lymphoma. J Clin Oncol. 2016;34(15):1757-1763.
  39. Rheingold SR, Tasian SK, Whitlock JA, et al. A phase 1 trial of temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukaemia: a Children's Oncology Group study (ADVL1114). Br J Haematol. 2017;177(3):467-474.
  40. Siracusa R, Paterniti I, Cordaro M, et al. Neuroprotective effects of temsirolimus in animal models of Parkinson's disease. Mol Neurobiol. 2018;55(3):2403-2419.
  41. Sherman EJ, Dunn LA, Ho AL, et al. Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer. Cancer. 2017;123(21):4114-4121.
  42. Dunn LA, Fury MG, Xiao H, et al. A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Ann Oncol. 2017;28(10):2533-2538.
  43. Chang HW, Wu MJ, Lin ZM, et al. Therapeutic effect of repurposed temsirolimus in lung adenocarcinoma model. Front Pharmacol. 2018;9:778.
  44. Pulido M, Roubaud G, Cazeau AL, et al. Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer. BMC Cancer. 2018;18(1):194.
  45. Schiff D, Jaeckle KA, Anderson SK, et al. Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572. Cancer. 2018;124(7):1455-1463.
  46. Tarek N, Hayes-Jordan A, Salvador L, et al. Recurrent desmoplastic small round cell tumor responding to an mTOR inhibitor containing regimen. Pediatr Blood Cancer. 2018;65(1).
  47. Hajatdoost L, Sedaghat K, Walker EJ, et al. Chemotherapy in pancreatic cancer: A systematic review. Medicina (Kaunas). 2018;54(3).
  48. Karavasilis V, Samantas E, Koliou GA, et al. Gemcitabine combined with the mTOR inhibitor temsirolimus in patients with locally advanced or metastatic pancreatic cancer. A Hellenic Cooperative Oncology Group Phase I/II Study. Target Oncol. 2018;13(6):715-724.
  49. Chen Z, Yang H, Li Z, et al. Temsirolimus as a dual inhibitor of retinoblastoma and angiogenesis via targeting mTOR signalling. Biochem Biophys Res Commun. 2019;516(3):726-732.
  50. National Comprehensive Cancer Network (NCCN). Temsirolimus. NCCN Drugs & Biologics Compendium. Fort Washington, PA: NCCN; 2019.
  51. Wyeth Pharmaceuticals Inc. Torisel Kit (temsirolimus) injection, for intravenous use. Prescribing Information. LAB-0461-10.0. Philadelphia, PA: Pfizer Inc.; revised April 2018.
  52. The NCCN Drugs & Biologics Compendium® © 2018 National Comprehensive Cancer Network, Inc. http://www.nccn.org. Accessed May 24, 2019.
  53. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Kidney Cancer. Version 4.2019. Accessed May 24, 2019. https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf.
  54. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Uterine Neoplasms. Version 3.2019. Accessed May 24, 2019. https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf.
  55. Oza AM, Elit L, Tsao MS, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol. 2011;29(24):3278-85.
  56. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Soft Tissue Sarcoma. Version 2.2019. Accessed May 24, 2019. https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf.
  57. Benson C, Vitfell-Rasmussen J, Maruzzo M, et al. A retrospective study of patients with malignant PEComa receiving treatment with sirolimus or temsirolimus: the Royal Marsden Hospital experience. Anticancer Res 2014;34:3663-8.